Pharmacokinetics of testosterone explained

The pharmacology of testosterone, an androgen and anabolic steroid (AAS) medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.

Testosterone is a naturally occurring and bioidentical AAS, or an agonist of the androgen receptor, the biological target of androgens like endogenous testosterone and dihydrotestosterone (DHT).

Testosterone is used by both men and women and can be taken by a variety of different routes of administration.

Routes of administration

Testosterone can be taken by a variety of different routes of administration. These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches, solutions), vaginal (creams, gels, suppositories), rectal (suppositories), by intramuscular or subcutaneous injection (in oil solutions or aqueous suspensions), and as a subcutaneous implant. The pharmacokinetics of testosterone, including its bioavailability, metabolism, biological half-life, and other parameters, differ by route of administration. Likewise, the potency of testosterone, and its local effects in certain tissues, for instance the liver, differ by route of administration as well. In particular, the oral route is subject to a high first-pass effect, which results in high levels of testosterone in the liver and consequent hepatic androgenic effects, as well as low potency due to first-pass metabolism in the intestines and liver into metabolites like dihydrotestosterone and androgen conjugates. Conversely, this is not the case for non-oral routes, which bypass the first pass.

Different testosterone routes and dosages can achieve widely varying circulating testosterone levels. For purposes of comparison with normal physiological circumstances, circulating levels of total testosterone in men range from about 250 to 1,100 ng/dL (mean 630 ng/dL) and in women range from about 2 to 50 ng/dL (mean 32 ng/dL).[1] [2] [3] [4] Testosterone levels decline with age in men. In women with polycystic ovary syndrome (PCOS), a condition of androgen excess, testosterone levels are typically around 50 to 80 ng/dL, with a range of about 30 to 140 ng/dL.[5] [6] Total testosterone levels are about 20-fold and free testosterone levels about 40-fold higher in men than in women on average.[7] Similarly, testosterone production is approximately 30 times higher in men than in women.[8]

Oral administration

Oral testosterone

Testosterone is well-absorbed but extensively metabolized with oral administration due to the first pass through the intestines and liver.[9] [10] [11] It is rapidly and completely inactivated in men at doses of less than 200 mg. In large doses, such as 200 mg however, significant increases in circulating testosterone levels become apparent. In addition, while a 60 mg dose has no effect on testosterone levels in men, this dose does measurably increase testosterone levels in prepubertal boys and women. The oral bioavailability of testosterone in young women after a single 25 mg dose was found to be 3.6 ± 2.5%.[12] High levels of testosterone are also achieved with a 60 mg dose of oral testosterone in men with liver cirrhosis. These findings are attributed to induction of liver enzymes by testosterone and consequent activation of its own metabolism. Substitution dosages of oral testosterone in men are in the range of 400 to 800 mg/day. Such doses exceed the amount of testosterone produced by the body, which is approximately 7 mg/day, by approximately 100-fold. The elimination half-life of oral testosterone is rapid at about 5 to 7 hours.[13] As a result, it requires administration several times per day in divided doses. Due to its limitations, such as the high doses required and necessity of multiple daily doses, oral testosterone is not used clinically in its unmodified form.

Oral testosterone has been studied in combination with a 5α-reductase inhibitor to reduce its first-pass metabolism and improve its bioavailability.[14] [15]

Oral testosterone undecanoate

Instead of in its free unesterified form, testosterone is used by oral administration in the form of testosterone undecanoate. Due to the unique chemical properties afforded by its long fatty acid ester chain, this testosterone ester is partially absorbed from the gastrointestinal tract into the lymphatic system, thereby bypassing a portion of first-pass metabolism in the liver and producing measurable increases in testosterone levels at much lower doses than free testosterone. Of oral testosterone undecanoate that reaches circulation, 90 to 100% is transported lymphatically. However, its duration remains short, with an elimination half-life of 1.6 hours and a mean residence time of 3.7 hours.[16] [17] Oral testosterone undecanoate is provided as 40 mg oil-filled capsules and requires administration 2 to 4 times per day (i.e., 80 to 160 mg/day) for substitution in men. It must be taken with food containing at least a moderate or "normal" amount of fat in order to achieve adequate absorption.[18] [19] [20] In addition, there is very high interindividual variability in levels of testosterone with oral testosterone undecanoate. The bioavailability of oral testosterone undecanoate taken with food is 3 to 7%.[21] [22] Inappropriately high levels of testosterone have been observed with 10 to 40 mg/day oral testosterone undecanoate in women.[23] [24] The oral bioavailability of testosterone undecanoate in young women after a single 40 mg dose was found to be 6.8 ± 3.3%.

A novel self-emulsifying formulation of oral testosterone undecanoate in 300-mg capsules for use once per day is under development.

First-pass effect and differences

Oral testosterone and oral testosterone undecanoate are not hepatotoxic, unlike orally administered 17α-alkylated anabolic steroids such as methyltestosterone and fluoxymesterone but similarly to parenteral routes and forms of bioidentical testosterone like injections.[25] [26]

Buccal administration

Testosterone can be used by buccal administration (e.g., brand name Striant).

Sublingual administration

Testosterone can be used by sublingual administration.[27] [28] A 10 mg sublingual tablet with the brand name Testoral was previously marketed for use one to four times per day in men.[29]

Inhalational administration

Testosterone has been studied by inhalation.[30]

Intranasal administration

Testosterone can be used by intranasal administration (e.g., brand name Natesto).

Transdermal administration

See also: Testosterone (patch).

Testosterone is available for transdermal administration in the form of gels, creams, scrotal and non-scrotal patches, and axillary solutions.

Transdermal testosterone gel has a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs.[31] [32] Scrotal skin is the thinnest skin of the body and has enhanced absorption characteristics relative to other skin areas.[33] [34] [35] [36] Application of testosterone gels and creams to the scrotum has been studied and achieves much higher levels of testosterone than conventional skin sites.[37] [38] [39] [40] Scrotal application of testosterone requires approximately 5-fold lower doses relative to non-scrotal application.[41]

The development of transdermal preparations of testosterone (and of progesterone)[42] has been more difficult than the case of estradiol.[43] This is because testosterone levels in men are about 100 to 1,000 times higher than estradiol levels in women (300 to 1,000 ng/dL vs. 50 to 150 pg/mL, respectively). Non-scrotal testosterone patches were assessed and were found to be ineffective in raising testosterone levels in men. As a result, scrotal testosterone patches were initially marketed. Subsequently, however, non-scrotal testosterone patches with special permeation enhancers that could successfully increase testosterone levels were developed and marketed. However, non-scrotal testosterone patches nonetheless require a large skin area for application (up to 60 cm2) and must be replaced daily.

Supraphysiological levels of dihydrotestosterone (DHT) occur with scrotal application of testosterone, whereas this does not occur with non-scrotal transdermal application. This is due to the high expression of 5α-reductase in scrotal skin. Estradiol levels are similar with scrotal versus non-scrotal application of transdermal testosterone.

Low-dose transdermal testosterone patches in women have been found to result in testosterone levels of 64 ng/dL with 150 μg/day and 102 ng/dL with 300 μg/day. When testosterone is used transdermally in women or trans men, hair growth at the application sites can happen.[44]

Vaginal administration

Testosterone can be used by vaginal administration of creams, suppositories, and vaginal rings available from compounding pharmacies.[45] [46] [47] [48] [49] [50]

Rectal administration

Testosterone was marketed as a suppository for rectal administration by Ferring Pharmaceuticals from the early 1960s under brand names such as Rektandron and Testosteron.[51] [52] Rectal administration of testosterone avoids the first-pass effect with oral administration similarly to other non-oral routes. A single 40 mg dose of rectal testosterone has been found to result in maximal testosterone levels of almost 1,200 ng/dL within 30 minutes. Subsequently, testosterone levels steadily decline, reaching levels of about 700 ng/dL after 4 hours and levels of about 400 ng/dL after 8 hours. Other studies have also assessed the use of rectal testosterone, with similar findings.[53] [54] [55] [56] Rectal use of testosterone requires administration two or three times per day to maintain adequate testosterone levels. The route is poorly accepted, owing to its inconvenience. Rectal testosterone has been used in transmasculine hormone therapy.[57]

Intramuscular injection

See also: Androgen ester.

Testosterone can be administered by intramuscular injection either as an aqueous suspension of testosterone or as an oil solution or aqueous suspension of testosterone esters such as testosterone propionate, testosterone enanthate, testosterone cypionate, testosterone undecanoate, and testosterone isobutyrate.[58] An even longer-acting testosterone ester that was developed but ultimately never marketed is testosterone buciclate. These preparations are prodrugs of progesterone that have a long-lasting depot effect when injected into muscle or fat, ranging from days to months in duration.

The bioavailability of drugs that are administered intramuscularly is generally almost 95%.[59]

As oil solutions by intramuscular injection, the elimination half-lives of testosterone esters are 0.8 days for testosterone propionate, 4.5 days for testosterone enanthate, 20.9 days (in tea seed oil) and 33.9 days (in caster oil) for testosterone undecanoate, and 29.5 days for testosterone buciclate. The pharmacokinetics of testosterone cypionate are said to be the same as those of testosterone enanthate, with "extremely comparable" patterns of testosterone release. Due to their varying and different elimination half-lives, the different intramuscular testosterone esters are administered with differing frequencies.[60] Testosterone propionate is injected two to three times per week, testosterone enanthate and testosterone cypionate are injected once every two to four weeks, and testosterone undecanoate and testosterone buciclate are injected once every 10 to 14 weeks. Due to its relatively short duration, testosterone propionate is now relatively little used and testosterone undecanoate is the preferred testosterone ester for intramuscular use. Testosterone undecanoate and testosterone buciclate can be injected intramuscularly as infrequently as four times per year.

High doses of testosterone esters by intramuscular injection have been studied in healthy young men.[61] Levels of testosterone with intramuscular injections of testosterone cypionate were about 700 ng/dL for 100 mg/week, 1100 ng/dL for 250 mg/week, and 2000 ng/dL for 500 mg/week.[62] In another study, testosterone levels with 600 mg/week testosterone enanthate by intramuscular injection were 2,800–3,200 ng/dL.[63]

Intramuscular injection of testosterone propionate as an oil solution, aqueous suspension, and emulsion has been compared.[64]

Intramuscular injection of testosterone-containing biodegradable microspheres has been studied.

Subcutaneous injection

See also: Androgen ester.

Testosterone esters like testosterone enanthate and testosterone cypionate can be given by subcutaneous injection instead of intramuscular injection. Studies have shown that subcutaneous injection of testosterone and closely related esters in oil like testosterone cypionate, testosterone enantate, and nandrolone decanoate is effective and has similar pharmacokinetics to intramuscular injection.[65] [66] [67] [68] [69] [70] [71]

Subcutaneous implant

Testosterone can be administered in the form of a subcutaneous pellet implant.

The bioavailability of testosterone when administered as a subcutaneous pellet implant is virtually 100%.[72] Levels of testosterone vary considerably between individuals, but are fairly constant within individuals. The absorption half-life of subdermal testosterone implants is 2.5 months. The replacement interval is once every four to six months.[73] A single 50 mg testosterone pellet implanted every 4 to 6 months has been found to result in testosterone levels of 70 to 90 ng/dL in women.

Intravenous injection

Testosterone esters like testosterone enanthate are hydrolyzed into testosterone so rapidly in the blood that testosterone and testosterone enanthate have nearly identical pharmacokinetics when administered via intravenous injection.

General

Absorption

The oral bioavailability of testosterone is very low.[74] [75] The bioavailability of oral testosterone undecanoate is 3 to 7%.[21] [22] Topical testosterone gels have a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs.[31] [32] The bioavailability of testosterone by subcutaneous implant is virtually 100%.[72] The bioavailability of drugs that are administered intramuscularly is generally almost 95%.[59]

Distribution

In the circulation, 97.0 to 99.5% of testosterone is bound to plasma proteins, with 0.5 to 3.0% unbound.[76] It is tightly bound to SHBG and weakly to albumin. Of circulating testosterone, 30 to 44% is bound to SHBG while 54 to 68% is bound to albumin. Testosterone that is unbound is referred to as free testosterone and testosterone that is bound to albumin is referred to as bioavailable testosterone. Unlike testosterone that is bound to SHBG, bioavailable testosterone is bound to plasma proteins weakly enough such that, similarly to free testosterone, it may be biologically active, at least to a certain extent. When referenced collectively (i.e., free, bioavailable, and SHBG-bound), circulating testosterone is referred to as total testosterone.

Metabolism

Testosterone is metabolized primarily in the liver mainly (90%) by reduction via 5α- and 5β-reductase and conjugation via glucuronidation and sulfation.[77] [78] The major urinary metabolites of testosterone are androsterone glucuronide and etiocholanolone glucuronide.

The elimination half-life of testosterone varies depending on the route of administration and formulation and on whether or not it is esterified. The elimination half-life of testosterone in the blood or by intravenous injection is only about 10 minutes.[16] Conversely, testosterone and testosterone esters in oil solution or crystalline aqueous suspension administered by intramuscular or subcutaneous injection have much longer half-lives, in the range of days to months, due to slow release from the injection site.

Elimination

Testosterone and its metabolites are eliminated in urine.[79] It is excreted mainly as androsterone glucuronide and etiocholanolone glucuronide.[80] It is also excreted to a small extent as other conjugates such as testosterone glucuronide (1%), testosterone sulfate (0.03%), and androstanediol glucuronides. Only a very small amount of testosterone (less than 0.01%) is found unchanged in the urine.[81]

See also

Further reading

Notes and References

  1. Book: Jameson JL, De Groot LJ . Endocrinology: Adult and Pediatric E-Book. 25 February 2015. Elsevier Health Sciences. 978-0-323-32195-2.
  2. Book: Chernecky CC, Berger BJ . Laboratory Tests and Diagnostic Procedures – E-Book. 31 October 2012. Elsevier Health Sciences. 978-1-4557-4502-9. 1059–1062.
  3. Book: Sperling MA . Pediatric Endocrinology E-Book: Expert Consult - Online and Print. 10 April 2014. Elsevier Health Sciences. 978-1-4557-5973-6. 488–.
  4. Steinberger E, Ayala C, Hsi B, Smith KD, Rodriguez-Rigau LJ, Weidman ER, Reimondo GG . Utilization of commercial laboratory results in management of hyperandrogenism in women . Endocrine Practice . 4 . 1 . 1–10 . 1998 . 15251757 . 10.4158/EP.4.1.1 .
  5. Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, Brzyski RG, Christman GM, Trussell JC, Krawetz SA, Snyder PJ, Ohl D, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Santoro N, Eisenberg E, Zhang M, Zhang H . 6 . Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism . The Journal of Clinical Endocrinology and Metabolism . 95 . 12 . 5305–5313 . December 2010 . 20826578 . 2999971 . 10.1210/jc.2010-1123 . free .
  6. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS . Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients . Human Reproduction . 10 . 8 . 2107–2111 . August 1995 . 8567849 . 10.1093/oxfordjournals.humrep.a136243 .
  7. Book: Styne DM . Physiology and Disorders of Puberty . 1023–1164 . Melmed S, Koenig RJ, Rosen CJ, Auchus R, Goldfine AB, Williams RH . Williams Textbook of Endocrinology . 14 . 6 December 2019 . Philadelphia, PA . Elsevier . 9780323555968 .
  8. Book: Liu OT, Handelsman DJ . Testosterone. Androgen therapy in non-gonadal disease. 1998. 473–512. Springer . 10.1007/978-3-642-72185-4_17. 978-3-642-72187-8.
  9. Book: Bain J, Schill WB, Schwarzstein L . Treatment of Male Infertility. 6 December 2012. Springer Science & Business Media. 978-3-642-68223-0. 176–177.
  10. Snyder PJ . Clinical use of androgens . Annual Review of Medicine . 35 . 1 . 207–217 . 1984 . 6372655 . 10.1146/annurev.me.35.020184.001231 .
  11. Book: Becker KL . Principles and Practice of Endocrinology and Metabolism . 2001 . Lippincott Williams & Wilkins . 978-0-7817-1750-2 . 1116, 1119, 1152, 1182–1185, 1195–1197, 2146 . live . https://web.archive.org/web/20170505210814/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1182 . May 5, 2017 . mdy-all .
  12. Täuber U, Schröder K, Düsterberg B, Matthes H . Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone . European Journal of Drug Metabolism and Pharmacokinetics . 11 . 2 . 145–149 . 1986 . 3770015 . 10.1007/BF03189840 . 32305408 .
  13. Johnsen SG, Bennett EP, Jensen VG . Therapeutic effectiveness of oral testosterone . Lancet . 2 . 7895 . 1473–1475 . December 1974 . 4140393 . 10.1016/S0140-6736(74)90216-5 .
  14. Book: Behre HM, Nieschlag E, Nieschlag S . Testosterone preparations for clinical use in males. Nieschlag E, Behre HM, Nieschlag S . 309–335. 10.1017/CBO9781139003353.016. Testosterone: Action, Deficiency, Substitution. 26 July 2012. Cambridge University Press. 978-1-107-01290-5.
  15. Corona G, Rastrelli G, Vignozzi L, Maggi M . Emerging medication for the treatment of male hypogonadism . Expert Opinion on Emerging Drugs . 17 . 2 . 239–259 . June 2012 . 22612692 . 10.1517/14728214.2012.683411 . 22068249 .
  16. Book: Nieschlag E, Behre HM, Nieschlag S . Andrology: Male Reproductive Health and Dysfunction . 13 January 2010 . Springer Science & Business Media . 978-3-540-78355-8 . 49–54,441–446 . live . https://web.archive.org/web/20160623203518/https://books.google.com/books?id=mEgckDNkonUC . June 23, 2016 . mdy-all .
  17. Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E . Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies . European Journal of Endocrinology . 140 . 5 . 414–419 . May 1999 . 10229906 . 10.1530/eje.0.1400414 . 22597244 . 10.1.1.503.1752 .
  18. Book: Hohl A . Testosterone: From Basic to Clinical Aspects. 30 March 2017. Springer. 978-3-319-46086-4. 13–.
  19. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS . Important effect of food on the bioavailability of oral testosterone undecanoate . Pharmacotherapy . 23 . 3 . 319–325 . March 2003 . 12627930 . 10.1592/phco.23.3.319.32104 . 24440953 .
  20. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB . The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps . Clinical Endocrinology . 66 . 4 . 579–585 . April 2007 . 17371478 . 1859980 . 10.1111/j.1365-2265.2007.02781.x .
  21. Book: Lemke TL, Williams DA . Foye's Principles of Medicinal Chemistry . 24 January 2012 . Lippincott Williams & Wilkins . 978-1-60913-345-0 . 1360– .
  22. Book: Touitou E, Barry BW . Enhancement in Drug Delivery . 27 November 2006 . CRC Press . 978-1-4200-0481-6 . 122– .
  23. Lobo RA . Androgens in postmenopausal women: production, possible role, and replacement options . Obstetrical & Gynecological Survey . 56 . 6 . 361–376 . June 2001 . 11466487 . 10.1097/00006254-200106000-00022 . 9872335 .
  24. Buckler HM, Robertson WR, Wu FC . Which androgen replacement therapy for women? . The Journal of Clinical Endocrinology and Metabolism . 83 . 11 . 3920–3924 . November 1998 . 9814469 . 10.1210/jcem.83.11.5280 . free .
  25. Nieschlag E, Nieschlag S . ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use . European Journal of Endocrinology . 180 . 6 . R201–R212 . June 2019 . 30959485 . 10.1530/EJE-19-0071 . free .
  26. Book: Byrne MM, Nieschlag E . Reference Module in Neuroscience and Biobehavioral Psychology. Androgens: Pharmacological Use and Abuse ☆. 2017. Elsevier . 10.1016/B978-0-12-809324-5.03356-3. 9780128093245.
  27. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS . 6 . Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study . The Journal of Clinical Endocrinology and Metabolism . 81 . 10 . 3654–3662 . October 1996 . 8855818 . 10.1210/jcem.81.10.8855818 . free .
  28. Escamilla RF, Gordan GS . Sublingual administration of testosterone compounds in male hypogonadism . Ciba Clinical Symposia . 3 . 2 . 49–56 . March 1951 . 14822123 .
  29. Book: Brotherton J . Sex Hormone Pharmacology. 1976. Academic Press. 978-0-12-137250-7. 18–19,331,336.
  30. Davison S, Thipphawong J, Blanchard J, Liu K, Morishige R, Gonda I, Okikawa J, Adams J, Evans A, Otulana B, Davis S . 6 . Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women . Journal of Clinical Pharmacology . 45 . 2 . 177–184 . February 2005 . 15647410 . 10.1177/0091270004269840 . 25919373 .
  31. Book: Jones H . Testosterone Deficiency in Men . 25 September 2008 . OUP Oxford . 978-0-19-954513-1 . 89– .
  32. Book: Rastrelli G, Reisman Y, Ferri S, Prontera O, Sforza A, Maggi M, Corona G . Testosterone Replacement Therapy . Sexual Medicine pp 79–93Cite as . 2019. 79–93. Springer . 10.1007/978-981-13-1226-7_8. 978-981-13-1225-0. 240176927.
  33. Book: Berth-Jones J . Rook's Textbook of Dermatology. Principles of Topical Therapy. 2016. 1–51. Wiley . 10.1002/9781118441213.rtd0018. 9781118441213.
  34. Benedetti MS, Whomsley R, Poggesi I, Cawello W, Mathy FX, Delporte ML, Papeleu P, Watelet JB . 6 . Drug metabolism and pharmacokinetics . Drug Metabolism Reviews . 41 . 3 . 344–390 . 2009 . 19601718 . 3086155 . 10.1080/10837450902891295 .
  35. Book: Wester RC, Maibach HI . Regional Variation in Percutaneous Absorption. 33–42. 10.3109/9780203904015-6. Bronaugh RL, Maibach HI . Topical Absorption of Dermatological Products. https://books.google.com/books?id=3tfKBQAAQBAJ&pg=PA33. 2 January 2002. CRC Press. 978-0-203-90401-5.
  36. Feldmann RJ, Maibach HI . Regional variation in percutaneous penetration of 14C cortisol in man . The Journal of Investigative Dermatology . 48 . 2 . 181–183 . February 1967 . 6020682 . 10.1038/jid.1967.29 . free .
  37. Kühnert B, Byrne M, Simoni M, Köpcke W, Gerss J, Lemmnitz G, Nieschlag E . Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial . European Journal of Endocrinology . 153 . 2 . 317–326 . August 2005 . 16061839 . 10.1530/eje.1.01964 .
  38. Iyer R, Mok SF, Savkovic S, Turner L, Fraser G, Desai R, Jayadev V, Conway AJ, Handelsman DJ . 6 . Pharmacokinetics of testosterone cream applied to scrotal skin . Andrology . 5 . 4 . 725–731 . July 2017 . 28334510 . 10.1111/andr.12357 . free .
  39. Amano T, Iwamoto T, Sato Y, Imao T, Earle C . The efficacy and safety of short-acting testosterone ointment (Glowmin) for late-onset hypogonadism in accordance with testosterone circadian rhythm . The Aging Male . 21 . 3 . 170–175 . September 2018 . 29734846 . 10.1080/13685538.2018.1471129 . 13701612 .
  40. Needham S, Needham S . Case Study: Absorption of Testosterone Cream via Scrotal Delivery . International Journal of Pharmaceutical Compounding . 22 . 6 . 466–468 . 2018 . 30384346 .
  41. Nieschlag E . Current topics in testosterone replacement of hypogonadal men . Best Practice & Research. Clinical Endocrinology & Metabolism . 29 . 1 . 77–90 . January 2015 . 25617174 . 10.1016/j.beem.2014.09.008 .
  42. Potts RO, Lobo RA . Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist . Obstetrics and Gynecology . 105 . 5 Pt 1 . 953–961 . May 2005 . 15863530 . 10.1097/01.AOG.0000161958.70059.db . 23411589 .
  43. Henzl MR, Loomba PK . Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice . The Journal of Reproductive Medicine . 48 . 7 . 525–540 . July 2003 . 12953327 .
  44. Book: Davis SR, Nieschlag E, Behre HM, Nieschlag S . Testosterone use in women . Nieschlag E, Behre HM, Nieschlag S . 494–516. 10.1017/CBO9781139003353.024. Testosterone: Action, Deficiency, Substitution. 26 July 2012. Cambridge University Press. 978-1-107-01290-5.
  45. Maia H, Casoy J, Valente J . Testosterone replacement therapy in the climacteric: benefits beyond sexuality . Gynecological Endocrinology . 25 . 1 . 12–20 . January 2009 . 19165658 . 10.1080/09513590802360744 . 40325624 .
  46. Book: Culligan PJ, Goldberg RP . Urogynecology in Primary Care. 6 March 2007. Springer Science & Business Media. 978-1-84628-167-9. 116–. Topical vaginal testosterone is often used in premenopausal women as a first step in the treatment of sexual dysfunction and vaginal lichen planus. Topical testosteorne preparations can be compounded in 1% to 2% formulations and should be applied up to 3 times per week..
  47. Book: Papadakis MA, McPhee SJ, Rabow MW . Current Medical Diagnosis and Treatment 2018, 57th Edition. 11 September 2017. McGraw-Hill Education. 978-1-259-86149-9. 1217–1218. Testosterone can also be compounded as a cream containing 1 mg/mL, with 1 mL applied to the abdomen daily. Vaginal testosterone is an option for postmenopausal women who cannot use systemic or vaginal estrogen due to breast cancer. Testosterone 150–300 mcg/day vaginally appears to reduce vaginal dryness and dyspareunia without increasing systemic estrogen levels..
  48. Book: Pizzorno JE . Textbook of Natural Medicine. 2013. Elsevier Health Sciences. 978-1-4377-2333-5. 1602–. At present, bioidentical testosterone can be obtained only from a compounding pharmacy, where 4 to 6 mg of bioidentical testosterone is generally formulated alone or together with the biestrogen or triestrogen formulation. Testosterone cream applied to the genital region can be used as an alternative delivery method. Common prescriptions are anywhere from 1 to 10 mg/g of cream..
  49. Morley JE, Perry HM . Androgens and women at the menopause and beyond . The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences . 58 . 5 . M409–M416 . May 2003 . 12730248 . 10.1093/gerona/58.5.M409 . free .
  50. Book: Lobo RA, Kelsey J, Marcus R . Menopause: Biology and Pathobiology. 22 May 2000. Academic Press. 978-0-08-053620-0. 455–.
  51. Book: Lauritzen C . Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien . 229–306 . Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles . Schneider HP, Lauritzen C, Nieschlag E . Grundlagen und Klinik der Menschlichen Fortpflanzung . Foundations and Clinic of Human Reproduction . de . 1988 . Walter de Gruyter . 978-3110109689 . 35483492 .
  52. Book: Apotekens informationsavdelning. Apotekens synonymregister över farmacevtiska specialiteter. 1964. Apotekens informationsavdelning.. Rektandron FERRING supp. 40 mg • individ. dos. • 10 st..
  53. Hamburger C . Testosterone treatment and 17-ketosteroid excretion. V. Administration of testosterone per rectum . Acta Endocrinologica . 28 . 4 . 529–536 . August 1958 . 13570882 . 10.1530/acta.0.0280529 .
  54. Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ . Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men . Hormone Research . 7 . 3 . 138–145 . 1976 . 1002121 . 10.1159/000178721 .
  55. Lentini S, Fortunio G . [Absorption and action of testosterone administered rectally] . Italian . Clinica Nuova; Rassegna del Progresso Medico Internazionale . 14 . 1–2 . 5–16 . 1952 . 14945075 . Absorption and action of testosterone administered rectally .
  56. Hamburger C . [Letter: Testosterone suppositories DAK] . Danish . Ugeskrift for Laeger . 136 . 6 . 307–308 . February 1974 . 4820554 . Letter: Testosterone suppositories DAK .
  57. Aakvaag A, Vogt JH . Plasma testosterone values in different forms of testosterone treatment . Acta Endocrinologica . 60 . 3 . 537–542 . March 1969 . 5395873 . 10.1530/acta.0.0600537 .
  58. Book: Llewellyn W . Anabolics. 2011. Molecular Nutrition Llc. 978-0-9828280-1-4. 212–216, 314–322.
  59. Book: Conceptual Pharmacology . 2010 . Universities Press . 978-81-7371-679-9 . 8– .
  60. Book: Yeung SC, Escalante CP, Gagel RF . Medical Care of Cancer Patients. 2009. PMPH-USA. 978-1-60795-008-0. 247–.
  61. Morgentaler A, Traish AM . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth . European Urology . 55 . 2 . 310–320 . February 2009 . 18838208 . 10.1016/j.eururo.2008.09.024 .
  62. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD . Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men . The Journal of Urology . 159 . 2 . 441–443 . February 1998 . 9649259 . 10.1016/s0022-5347(01)63944-2 .
  63. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R . 6 . The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men . The New England Journal of Medicine . 335 . 1 . 1–7 . July 1996 . 8637535 . 10.1056/NEJM199607043350101 . 73721690 . free .
  64. Book: Hamburger C . Ciba Foundation Symposium - Steroid Hormone Administration (Book II of Colloquia on Endocrinology, Vol. 3). 17-Ketosteroid Excretion and Modes of Administering Testosterone Preparations. 1952. 304–322. 1935-4657. 10.1002/9780470715154.ch7. Novartis Foundation Symposia. John Wiley & Sons . 9780470715154.
  65. Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D . Subcutaneous administration of testosterone. A pilot study report . Saudi Medical Journal . 27 . 12 . 1843–1846 . December 2006 . 17143361 .
  66. Deutsch MB, Bhakri V, Kubicek K . Effects of cross-sex hormone treatment on transgender women and men . Obstetrics and Gynecology . 125 . 3 . 605–610 . March 2015 . 25730222 . 4442681 . 10.1097/AOG.0000000000000692 .
  67. Olson J, Schrager SM, Clark LF, Dunlap SL, Belzer M . Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men . LGBT Health . 1 . 3 . 165–167 . September 2014 . 26789709 . 10.1089/lgbt.2014.0018 .
  68. Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt LV, Eimicke T, Olshan JS . 6 . Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients . The Journal of Clinical Endocrinology and Metabolism . 102 . 7 . 2349–2355 . July 2017 . 28379417 . 10.1210/jc.2017-00359 . free .
  69. McFarland J, Craig W, Clarke NJ, Spratt DI . Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone . Journal of the Endocrine Society . 1 . 8 . 1095–1103 . August 2017 . 29264562 . 5686655 . 10.1210/js.2017-00148 .
  70. Wilson DM, Kiang TK, Ensom MH . Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study . American Journal of Health-System Pharmacy . 75 . 6 . 351–358 . March 2018 . 29367424 . 10.2146/ajhp170160 . 3886536 .
  71. Singh GK, Turner L, Desai R, Jimenez M, Handelsman DJ . Pharmacokinetic-pharmacodynamic study of subcutaneous injection of depot nandrolone decanoate using dried blood spots sampling coupled with ultrapressure liquid chromatography tandem mass spectrometry assays . The Journal of Clinical Endocrinology and Metabolism . 99 . 7 . 2592–2598 . July 2014 . 24684468 . 10.1210/jc.2014-1243 . free .
  72. Book: Bhasin S . Pharmacology, Biology, and Clinical Applications of Androgens: Current Status and Future Prospects . 13 February 1996. John Wiley & Sons. 978-0-471-13320-9. 462–.
  73. Book: Kumar P, Clark ML . Kumar and Clark's Clinical Medicine. 4 June 2012. Elsevier Health Sciences. 978-0-7020-5304-7. 976–.
  74. Book: Nieschlag E, Behre HM . Testosterone: Action - Deficiency - Substitution. 6 December 2012. Springer Science & Business Media . 978-3-642-72185-4. 1–,9,298,309–331,349–353,366–367.
  75. Book: Karch SB . Drug Abuse Handbook, Second Edition. 21 December 2006. CRC Press. 978-1-4200-0346-8. 700–.
  76. Book: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM . Williams Textbook of Endocrinology. 11 November 2015. Elsevier Health Sciences. 978-0-323-34157-8. 709, 711, 765.
  77. Book: Wecker L, Watts S, Faingold C, Dunaway G, Crespo L . Brody's Human Pharmacology . 1 April 2009 . Elsevier Health Sciences . 978-0-323-07575-6 . 468–469 .
  78. Book: Becker KL . Principles and Practice of Endocrinology and Metabolism . 2001 . Lippincott Williams & Wilkins . 978-0-7817-1750-2 . 1116, 1119, 1183 . live . https://web.archive.org/web/20140628110255/http://books.google.com/books?id=FVfzRvaucq8C . June 28, 2014 . mdy-all .
  79. Book: Karch SB, Drummer O . Karch's Pathology of Drug Abuse . third . 26 December 2001 . CRC Press . 978-1-4200-4211-5 . 486– .
  80. Book: Thieme D, Hemmersbach P . Doping in Sports . 18 December 2009 . Springer Science & Business Media . 978-3-540-79088-4 . 53– .
  81. Book: Labhart A . Clinical Endocrinology: Theory and Practice. 6 December 2012. Springer Science & Business Media. 978-3-642-96158-8. 450–.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pharmacokinetics of testosterone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.